EPITIQUE (EPTQ) 500
Epitique (e.p.t.q.)
Dermal FillerHigh-density cross-linked hyaluronic acid dermal filler
Certifications
- CE Marked medical device dermal filler (E.P.T.Q line – CE certificate number commonly referenced as CE 2292 for the range).
- Manufactured under ISO 13485 and Good Manufacturing Practice (GMP) quality systems (as reported for the e.p.t.q. range).
- Korean MFDS (KFDA) approval for hyaluronic acid dermal filler indications (for the e.p.t.q. portfolio).
- Low endotoxin and residual BDDE levels in line with international safety standards for cross Linked HA fillers.
- All products supplied by Aesthetics Warehouse are stated as CE or CPNP registered where required.
- CE Marked medical device dermal filler (E.P.T.Q line – CE certificate number commonly referenced as CE 2292 for the range).
- Manufactured under ISO 13485 and Good Manufacturing Practice (GMP) quality systems (as reported for the e.p.t.q. range).
- Korean MFDS (KFDA) approval for hyaluronic acid dermal filler indications (for the e.p.t.q. portfolio).
- Low endotoxin and residual BDDE levels in line with international safety standards for cross Linked HA fillers.
- All products supplied by Aesthetics Warehouse are stated as CE or CPNP registered where required.
High-density cross-linked hyaluronic acid dermal filler
Description
EPITIQUE (EPTQ) 500 is a CE-marked, monophasic, high-density, cross-linked hyaluronic acid dermal filler with lidocaine, designed for advanced facial sculpting and correction of severe volume loss. With 24 mg/ml of non-animal, highly purified HA and 0.3% lidocaine, it delivers significant volume enhancement and contouring of areas such as cheeks, jawline, chin and nasal bridge, while minimising swelling and migration. Its high viscoelasticity and cohesive gel structure support precise, long-lasting results when injected by trained healthcare professionals.
Bnefits
- Biocompatible, non-animal hyaluronic acid integrates naturally into the skin for smooth, natural-looking results.
- High-density, highly cross-linked gel provides powerful lifting capacity and volume restoration for severe volume loss.
- Minimised migration for accurate sculpting and stable, well-defined contours.
- Lidocaine 0.3% is included to enhance patient comfort and provide a smoother injection experience.
- Monophasic, homogeneous gel with optimised injection pressure for consistent, even extrusion and injector control.
- High-purity HA with endotoxin level typically below 0.1 EU/ml to reduce the risk of post-treatment swelling and inflammatory reactions.
- Formulated using advanced manufacturing processes (e.g. ZEEP / “9 Process”) to ensure low residual BDDE and high safety.
- CE-marked dermal filler suitable for professional aesthetic use in the UK and EU.
- Designed to deliver long-lasting results, typically up to 12–18 months depending on treatment area and patient factors.
Indications
- Correction of severe facial wrinkles and folds (e.g. deep nasolabial folds, marionette lines) in appropriately selected patients.
- Restoration of volume in hollow cheeks and temporal regions.
- Jawline and chin augmentation for improved definition and contour.
- Non-surgical nasal bridge augmentation (liquid rhinoplasty by trained specialists).
- Lip augmentation and enhancement where a high-density filler is clinically appropriate.
- General mid-face and lower-face contouring for significant volume loss, when used by trained healthcare professionals.
Composition
- Cross-linked hyaluronic acid 24 mg/ml (non-animal origin).
- Lidocaine hydrochloride 0.3% as a local anaesthetic.
- Physiological buffer solution adjusted to body-like pH (exact buffer components not publicly detailed).
- Highly purified HA with endotoxin content typically <0.1 EU/ml.
- Residual BDDE reported by the brand to be below commonly accepted safety thresholds (e.g. <2 ppm).
Formulation
- Monophasic, high-density, cross-linked hyaluronic acid gel.
- High viscoelasticity and cohesiveness to provide strong structural support and lifting effect.
- Designed for deep dermal, subcutaneous or supraperiosteal injection, depending on the treatment area and technique.
- Non-animal, biotechnologically produced HA, purified and stabilised for aesthetic use.
Packaging
- Box containing 1 x 1.1 ml pre-filled, sterile syringe of EPITIQUE (EPTQ) 500.
- Includes 1 x 25G needle and 1 x 27G needle (supplied sterile).
- Single-use, disposable syringe and needles, packaged in a sterile blister.
- Outer carton with product labelling, batch number and expiry date; instructions for use (IFU) supplied by manufacturer or distributor.
Usage
- For professional use only; must be administered exclusively by appropriately trained and qualified healthcare practitioners in accordance with local regulations.
- Intended injection depth is typically the deep dermis, subcutaneous tissue or supraperiosteal plane, depending on indication and clinical judgement.
- Recommended needle sizes are generally 25G or 27G, as supplied; cannulas may be used where clinically appropriate following current guidelines.
- Prior to injection, perform a full medical assessment, including history of allergies, previous filler treatments, medications, and risk factors for vascular events.
- Cleanse and disinfect the treatment area thoroughly and follow strict aseptic technique throughout the procedure.
- Inject slowly with minimal pressure, using small aliquots and appropriate techniques (e.g. linear threading, fanning, depot) while continually aspirating and monitoring for signs of intravascular injection.
- Avoid injection into blood vessels and high-risk anatomical zones unless appropriately trained and using recognised safe techniques.
- Massage gently if required to mould the product and achieve the desired contour, following the manufacturer’s and practitioner’s protocols.
- Advise patients on post-procedure care, including avoiding extreme temperatures, vigorous exercise, make-up on treated areas and alcohol for a specified period, as well as monitoring for signs of complications.
- Ensure ready access to emergency medications and protocols for immediate management of complications such as vascular occlusion, hypersensitivity or anaphylaxis.
- Do not use if the packaging is damaged, the syringe or needles are compromised, or the product is past its expiry date.
Contraindications
- Hypersensitivity or known allergy to hyaluronic acid, lidocaine, amide-type local anaesthetics, or any other component of the product.
- Presence of active skin infection, inflammation, herpes simplex, or dermatological disease at or near the intended injection site.
- History of severe allergy, anaphylaxis, or multiple severe allergies without appropriate risk assessment and emergency preparedness.
- Patients with autoimmune diseases or immunocompromised status should be treated with caution and only after thorough clinical evaluation.
- Bleeding disorders, use of anticoagulants or antiplatelet therapy that significantly increase bleeding risk (relative contraindication; requires individual risk–benefit assessment).
- Pregnant or breastfeeding patients, due to lack of adequate safety data.
- History of hypertrophic scarring or keloid formation in the proposed treatment area.
- Previous permanent or semi-permanent fillers in the same area without careful assessment of interactions and risk of granuloma or migration.
Adverse Effects
- Common, usually transient reactions at the injection site such as erythema, swelling, tenderness, pain, itching, bruising or mild induration.
- Local haematoma or ecchymosis due to needle trauma.
- Temporary asymmetry or overcorrection, typically resolving as swelling subsides or with appropriate management.
- Nodules, palpable lumps, or irregularities, which may require massage or further clinical management.
- Hypersensitivity reactions or delayed inflammatory responses, including redness, swelling or induration that persist or recur.
- Rare but serious adverse events such as vascular occlusion, skin blanching, tissue ischaemia and necrosis, or visual disturbance/vision loss if inadvertently injected into or compressing a blood vessel.
- Very rare risk of infection, abscess, granuloma formation or biofilm; may require medical or surgical intervention.
- Systemic reactions related to lidocaine (e.g. dizziness, paraesthesia, tachycardia) if significant systemic absorption occurs, especially with high volumes or intravascular injection.
Storage Conditions
- Store between 2°C and 25°C in a dry place.
- Do not freeze the product.
- Protect from direct sunlight and excessive heat.
- Keep the syringe in its original packaging until use to maintain sterility.
- Do not use after the expiry date printed on the packaging.
- Keep out of the sight and reach of children.
Duration
Results are typically long-lasting, with clinical effect commonly maintained for approximately 12\u201318 months depending on injection site, technique, patient metabolism and lifestyle.
Onset
Volume enhancement and contouring are usually visible immediately after injection, with final results evident once initial swelling and redness subside over several days to approximately 1\u20132 weeks.
